Entera Bio Ltd Net Assets
Entera Bio Ltd net assets. Based on the latest financial reports, Entera Bio Ltd (ENTX) has net assets worth $7.27 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.48 Million) and total liabilities ($12.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Entera Bio Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.27 Million |
| % of Total Assets | 37.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -41.94% |
| 10-Year Change | N/A |
| Growth Volatility | 80.11 |
Net Assets of Entera Bio Ltd (2015–2025)
Net assets of Entera Bio Ltd from 2015 to 2025. This chart illustrates how Entera Bio Ltd's net assets have evolved over time, based on quarterly financial data. See ENTX equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Entera Bio Ltd (2015–2025)
The table below shows the annual net assets of Entera Bio Ltd from 2015 to 2025. For live market cap and overall valuation, see market cap of Entera Bio Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $13.10 Million | +62.14% |
| 2024-12-31 | $8.08 Million | -22.20% |
| 2023-12-31 | $10.39 Million | -11.64% |
| 2022-12-31 | $11.75 Million | -47.91% |
| 2021-12-31 | $22.57 Million | +200.47% |
| 2020-12-31 | $7.51 Million | -36.99% |
| 2019-12-31 | $11.92 Million | +17.82% |
| 2018-12-31 | $10.12 Million | +132.06% |
| 2017-12-31 | $-31.56 Million | -25.00% |
| 2016-12-31 | $-25.25 Million | +1.72% |
| 2015-12-31 | $-25.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entera Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9594900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Entera Bio Ltd Net Assets Breakdown (December 2025)
Entera Bio Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.01% |
| Other Comprehensive Income | $41.00K | 0.31% |
| Other Components | $138.43 Million | 1056.60% |
| Total Equity | $13.10 Million | 100.00% |
Entera Bio Ltd Competitors by Market Cap
The table below lists competitors of Entera Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EUROSEAS LTD DL -01
F:2LE1
|
$434.61 Million |
|
Universal Logistics Holdings Inc
NASDAQ:ULH
|
$434.71 Million |
|
Plastika Kritis S.A.
AT:PLAKR
|
$435.33 Million |
|
Vietnam Construction and Import Export JSC
VN:VCG
|
$435.46 Million |
|
CCCG Real Estate Corp Ltd
SHE:000736
|
$434.02 Million |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
$433.85 Million |
|
Gray Television Inc
NYSE:GTN
|
$433.83 Million |
|
Elevra Lithium Limited
AU:ELV
|
$433.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entera Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,080,000 to 13,101,000, a change of 5,021,000 (62.1%).
- Net loss of 11,439,000 reduced equity.
- New share issuances of 13,444,000 increased equity.
- Other factors increased equity by 3,016,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.44 Million | -87.31% |
| Share Issuances | $13.44 Million | +102.62% |
| Other Changes | $3.02 Million | +23.02% |
| Total Change | $- | 62.14% |
Book Value vs Market Value Analysis
This analysis compares Entera Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-2.16 | $3.05 | x |
| 2016-12-31 | $-2.12 | $3.05 | x |
| 2017-12-31 | $-2.65 | $3.05 | x |
| 2018-12-31 | $0.88 | $3.05 | x |
| 2019-12-31 | $0.98 | $3.05 | x |
| 2020-12-31 | $0.41 | $3.05 | x |
| 2021-12-31 | $0.86 | $3.05 | x |
| 2022-12-31 | $0.41 | $3.05 | x |
| 2023-12-31 | $0.36 | $3.05 | x |
| 2024-12-31 | $0.21 | $3.05 | x |
| 2025-12-31 | $0.28 | $3.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entera Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27235.71%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-87.31%) is below the historical average (-71.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.71 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $1.33 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.04 Million |
| 2018 | -101.86% | -2060.80% | 0.04x | 1.32x | $-11.32 Million |
| 2019 | -90.57% | -4574.15% | 0.01x | 1.40x | $-11.99 Million |
| 2020 | -132.93% | -2735.07% | 0.04x | 1.29x | $-10.73 Million |
| 2021 | -54.01% | -2134.33% | 0.02x | 1.15x | $-14.44 Million |
| 2022 | -111.20% | -9754.48% | 0.01x | 1.12x | $-14.25 Million |
| 2023 | -85.59% | -63492.86% | 0.00x | 1.13x | $-9.93 Million |
| 2024 | -118.08% | -5271.27% | 0.02x | 1.16x | $-10.35 Million |
| 2025 | -87.31% | -27235.71% | 0.00x | 1.22x | $-12.75 Million |
Industry Comparison
This section compares Entera Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entera Bio Ltd (ENTX) | $7.27 Million | 0.00% | 1.68x | $434.59 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more